로딩 중...
52주 최고가 대비 71.5% 위치
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $3.37B | $3.66B | $3.90B | $4.30B |
| 영업이익 | - | $898.8M | $1.10B | $1.13B | $1.36B |
| 당기순이익 | - | $679.1M | $845.0M | $887.9M | $1.06B |
| 잉여현금흐름 (FCF) | - | $384.1M | $772.9M | $798.1M | $1.04B |
| 수익성 비율 | |||||
| 영업이익률 | - | 26.7% | 30.0% | 29.0% | 31.6% |
| 순이익률 | - | 20.2% | 23.1% | 22.8% | 24.6% |
| ROE (자기자본이익률) | - | 111.6% | 56.9% | 55.7% | 66.0% |
| ROA (자산이익률) | - | 24.7% | 25.9% | 27.0% | 31.6% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 8.7% | 6.5% | 10.4% |
| EPS 성장률 (YoY) | - | - | 25.3% | 6.1% | 22.6% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 59.8x | 51.2x | 39.6x | 51.3x |
| PBR (주가순자산배수) | - | 62.3x | 27.4x | 20.9x | 32.9x |
| PSR (주가매출배수) | - | 11.3x | 11.1x | 8.5x | 12.3x |
| FCF Yield | - | 1.0% | 1.9% | 2.4% | 2.0% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 2.41 | 0.72 | 0.62 | 0.61 |
| 유동비율 | - | 0.89 | 1.57 | 1.31 | 1.23 |
MOLINA HEALTHCARE INC
$179.86
$9.4B